New methods advance treatment for respiratory distress syndrome

Pediatric Annals

Volumn 32, Issue 9, 2003, Pages 585-591

  Krauss, Alfred N ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CORTICOSTEROID; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; NITRIC OXIDE;

ASSISTED VENTILATION; BAROTRAUMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HUMAN; LUNG INJURY; LUNG INSUFFICIENCY; NEONATAL RESPIRATORY DISTRESS SYNDROME; OXYGEN TOXICITY; PRENATAL CARE; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; VASODILATATION;

EID: 0041886479     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20030901-07     Document Type: Review

References (34)

1. Krauss AN. Recent advances in hyaline membrane disease. Pediatr Ann. 1983;12(1):24-30.
2. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child. 1959;97:517-523.
3. Clements JA. Lung surfactant: A personal perspective. Annu Rev Physiol. 1997;59:1-21.
4. Jobe AH, Ikegami M. Biology of surfactant. Clin Perinatol. 2001;28(3):655-669.
5. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. New Eng J Med. 2002;347(26):2141-2148.
6. Liggins GC. Premature delivery of fetal lambs infused with glucocorticoids. J Endocrinol. 1969;45:515.
7. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-525.
8. American Academy of Pediatrics. Guidelines for Perinatal Care. 5th ed. Elk Grove, Ill: AAP; 2002:170-171.
9. Suresh GK, Soll RF. Current surfactant use in premature infants. Clin Perinatol. 2001;28(3):671-694.
10. Drugdex Drug Evaluations. Beractant. Micromedex Healthcare Series 2003;vol. 115.
11. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics. 1996;97(1):48-52.
12. Herting E, Gefeller O, Land M, et al., Collaborative European Multicenter Study Group. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics. 2000;106(5):957-964.
13. Wiswell TE. Expanded uses of surfactant therapy. Clin. Perinatol. 2001;28(3):695-711.
14. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease: Bronchopulmonary dysplasia. New Eng J Med. 1967;276(7):357-368.
15. Philip AG. Oxygen plus pressure plus time: The etiology of bronchopulmonary dysplasia. Pediatrics. 1975;55(1):44-50.
16. Avery ME, Tooley WH, Keller JB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics. 1987;79(1):26-30.
17. Greenough A. Update of patient-triggered ventilation. Clin Perinatol. 2001;28(3):533-546.
18. Ware LB, Matthay MA. The acute respiratory distress syndrome. New Eng J Med. 2000;342(18):1334-1349.
19. Carlo WA, Stark AR, Wright LL, et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely low-birth-weight infants. J Pediatrics. 2002;141(3):370-375.
20. Coghill CH, Carlo WA, Martin RJ. High-frequency jet ventilation. In: Boynton BR, Carlo WA, Jobe AH, eds. New Therapies for Neonatal Respiratory Failure: a physiological approach. New York, NY: Cambridge University Press; 1994:218-259.
21. Johnson AH, Peacock JL, Greenough A, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. New Eng J Med. 2002;347(9):633-642.
22. Courtney SE, Durand DJ, Asselin JM, et al. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. New Eng J Med. 2002;347(9):643-652.
23. Gersony WM. Persistence of the fetal circulation: a commentary. J Pediatr. 1973;82(6):1103-1106.
24. Bartlett RH, Roloff DW, Cornell RG, et al. Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study. Pediatrics. 1985;76(4):479-487.
25. Rudolph AM, Yuan S. Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest. 1966;45(3):399-411.
26. Peckham GJ, Fox WW. Physiologic factors affecting pulmonary artery pressure in infants with persistent pulmonary hypertension. J Pediatrics. 1978;93(6):1005-1010.
27. Shalak L, Perlman JM. Hemorrhagic-ischemic cerebral injury in the preterm infant: current concepts. Clin Perinatol. 2002;29(4):745-763.
28. Fujimoto S, Togari H, Yamaguchi N, et al. Hypocarbia and cystic periventricular leukomalacia in premature infants. Arch Dis Child. 1994;71(2):F107-110.
29. Bifano EM, Pfannenstiel A. Duration of hyperventilation and outcome in infants with persistent pulmonary hypertension. Pediatrics. 1988;81(4):657-661.
30. Roberts JD, Abman SH. Physiology of nitric oxide in the perinatal lung. In: Boynton BR, Carlo WA, Jobe AH, eds. New Therapies for Neonatal Respiratory Failure: a physiological approach. New York, NY: Cambridge University Press; 1994:339-348.
31. Walsh MC, Stork EK. Persistent pulmonary hypertension of the newborn. Clin. Perinatol. 2001;28(3):609-627.
32. Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide in term and near-term infants: Neurodevelopmental follow-up of NINOS. J Pediatrics. 2000;136(5):611-617.
33. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
34. American Academy of Pediatrics Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics. 2000;106(2 Pt 1):344-345.